"Neurotoxicity Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neurologic disorders caused by exposure to toxic substances through ingestion, injection, cutaneous application, or other method. This includes conditions caused by biologic, chemical, and pharmaceutical agents.
| Descriptor ID |
D020258
|
| MeSH Number(s) |
C10.720 C25.723.705
|
| Concept/Terms |
Neurotoxicity Syndromes- Neurotoxicity Syndromes
- Neurotoxicity Syndrome
- Syndrome, Neurotoxicity
- Syndromes, Neurotoxicity
- Neurotoxin Disorders
- Neurotoxin Disorder
- Neurotoxic Disorders
- Neurotoxic Disorder
- Neurotoxin Diseases
- Neurotoxin Disease
- Poisoning, Nervous System
- Nervous System Poisonings
- Poisonings, Nervous System
- Nervous System Poisoning
Encephalopathy, Toxic- Encephalopathy, Toxic
- Encephalopathies, Toxic
- Toxic Encephalopathies
- Toxic Encephalopathy
Toxic Encephalitis- Toxic Encephalitis
- Encephalitides, Toxic
- Encephalitis, Toxic
- Toxic Encephalitides
|
Below are MeSH descriptors whose meaning is more general than "Neurotoxicity Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Neurotoxicity Syndromes".
This graph shows the total number of publications written about "Neurotoxicity Syndromes" by people in this website by year, and whether "Neurotoxicity Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 1 | 3 |
| 2014 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 3 | 4 |
| 2025 | 2 | 0 | 2 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurotoxicity Syndromes" by people in Profiles.
-
Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients. Hematol Oncol Stem Cell Ther. 2026 Jan-Mar 01; 19(1):10-17.
-
Impact of Population Pharmacogenomics on Cisplatin-Induced Neurotoxicities in Testicular Cancer Survivors. Cancer Med. 2025 Sep; 14(17):e71218.
-
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Jul; 31(7):419-433.
-
Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study. J Patient Rep Outcomes. 2023 11 10; 7(1):113.
-
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023 09 26; 7(18):5579-5585.
-
Infectious complications of car T-cell therapy: A longitudinal risk model. Transpl Infect Dis. 2023 Nov; 25 Suppl 1:e14148.
-
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023 07; 29(7):449.e1-449.e7.
-
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023 03 14; 7(5):768-777.
-
Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Med. 2022 07; 11(14):2801-2816.
-
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022 04; 28(4):713-723.